PatentAug 4, 2026, 08:17 AM
Autonomix Medical Secures New US Patent for Nerve-Targeting Tech
AI Summary
Autonomix Medical, Inc. announced the issuance of U.S. Patent No. 12,433,670, titled "Systems and Methods for Treating Cancer and/or Augmenting Organ Function." This patent expands the company's intellectual property protection for technologies designed to sense, map, and selectively target nerves associated with tumors, cancer-related pain, organ function, and other autonomic nervous system disorders. The technology utilizes minimally invasive, catheter-based microsurgical tools to guide targeted treatment and modulate neural pathways, strengthening Autonomix's platform across oncology and autonomic nervous system applications.
Key Highlights
- U.S. Patent No. 12,433,670 issued to Autonomix Medical.
- Patent titled "Systems and Methods for Treating Cancer and/or Augmenting Organ Function."
- Expands IP protection for technology sensing, mapping, and targeting nerves.
- Covers minimally invasive systems for electrophysiological activity in nerves associated with tumors.
- Includes catheter-based microsurgical tools to record neural signals and deliver energy/agents.
- Describes applications for pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers.
Price Impact
More from AMIX